

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Canadian International Pharma Corp.
2489 Bellevue Avenue
West Vancouver, British Columbia V7V 1E1

(the "Company" or "CIPC")

Item 2 Date of Material Change

December 20, 2016

Item 3 News Release

Issued in West Vancouver, B.C. on December 20, 2016 and disseminated through the facilities of Market News and Stockwatch.

Item 4 Summary of Material Change

Canadian International Pharma Corp. Obtains Initial PharmaCert Order

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

CIPC announced that it has received an initial order from Nano Hayat Darou Company ("Nano"), a division of CinnaGen Co. based in Iran, to test a sample under its PharmaCert Program.

This is the initial step for Nano in the PharmaCert process. Once the product has been tested and should it meet all of the criteria, CIPC will provide a PharmaCert certification which assures the manufacturer, distributor, regulator and consumer that the medication adheres to Canadian Good Manufacturing Practices ("GMP") standards of quality, safety and effectiveness. The Company believes that with a successful testing and certification, Nano intends to place an order under the PharmaCert Program, the size of which will be dependent on the batch produced, and that Nano anticipates multiple nutraceuticals and medications to go through the PharmaCert Program.

PharmaCert Program

PharmaCert is a certification program for finished dosage forms of nutraceutical and pharmaceutical medications. The PharmaCert certification states that the medication has been tested and retested using rigorous and globally respected Canadian or US standards that measure the identity, strength, quality and purity of the medication based on trusted standards, such as United States Pharmacopeia, British Pharmacopeia or other high standard of Pharmacopeia.

About CinnaGen Co.

CinnaGen Co. was founded in 1994 and has grown to become the biggest bio-pharmaceutical manufacturer and biotech exporter in Iran. The company is focused on developing the bio-similar candidates in the areas of immunological diseases, infertility, hormone disorders and oncology as well as providing contract research development services. The Company is spending over 30 percent of its total turnover on R&D activities. It is CinnaGen's aim to use its expertise to identify and acquire selected products through strategic partnerships to promote sustainable development in human health.

About Canadian International Pharma Corp.

Canadian International Pharma Corp. ("CIPC" or the "Company") is an emerging multi-faceted pharmaceutical company that is in the process of developing generic and nutraceutical drug manufacturing, distribution and sales. CIPC has recently launched its PharmaCert Program. PharmaCert is a certification program for testing and measuring finished dosage forms of nutraceutical and pharmaceutical medications. The Company has also aligned itself with Canadian and US manufacturers with the objective of manufacturing generics and nutraceuticals for Canadian and overseas markets.

For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit the Company's website at www.canpharmacorp.ca.

5.2 Disclosure for Restructuring Transactions

Not Applicable.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable

Item 7 Omitted Information

No information has been intentionally omitted from this form.

Item 8 Executive Officers

The name and business telephone number of an executive officer of the Corporation who is knowledgeable about the material change and this report is:

Douglas L. Mason, CEO
Telephone: (604) 922-2030

Further information may be obtained from Bruce E. Morley, corporate counsel for the Company, at (604) 922-2030.

Item 9 Date of Report

This report is dated the 20th day of December, 2016.